middle.news
How Will Chimeric’s $8.4M Boost and FDA Nod Shape Its Cancer Therapy Trials?
9:52am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
How Will Chimeric’s $8.4M Boost and FDA Nod Shape Its Cancer Therapy Trials?
9:52am on Wednesday 28th of January, 2026 AEDT
Key Points
75% disease control in CHM CDH17 CAR-T Phase 1/2 trial for gastrointestinal cancers
FDA grants Orphan Drug Designation for CHM CDH17 in gastric cancer
Additional complete responses achieved in CORE-NK Phase 1b AML trial
$8.4 million raised via placement and convertible note to fund CHM CDH17 trial through Phase 1
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHIMERIC THERAPEUTICS (ASX:CHM)
OPEN ARTICLE